Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic Alpha Clinic Contact Trial Sponsor Disease Indicationsort descending Clinical Trial Name Status of Enrollment Learn More
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Kite Pharma Advanced Cancer A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Longeveron Aging frailty Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
BrainStorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis B-Cell Leukemia A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies Recruiting
UCSF
Romobia Hutchinson
415-476-9326
romobia.hutchinson@ucsf.edu
UCSF Blood Disorder - Alpha Thalassemia Major In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Recruiting
UCSF
& UCLA
Marci Moriarty, BSN, RN
510-428-3885 ext 5396
mmoriarty@mail.cho.org
Bruck Habtemariam
310-794-0242
bhabtemariam@mednet.ucla.edu
Sangamo Therapeutics Blood Disorder - Beta-Thalassemia A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) Recruiting
UCLA
& UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu
UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements Active, not recruiting
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens Recruiting
UCSD Persimmune, Inc. Cancer - Blood Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
UCI
& UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Recruiting
City of Hope
Behnam Badie, MD;
626-256-4673
bbadie@coh.org
City of Hope Cancer - Brain Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu
Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Recruiting
UCSF
Julie DeCaris
510-428-3885 ext 2739
jdecaris@mail.cho.org
Seattle Children's Hospital Foundation Cancer - Leukemia A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Long-Term Follow-up Study for Patients Previously Treated With JCAR015 No longer active
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
UCSD
& City of Hope
UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
Karen Reckamp, MD
626-218-9200
kreckamp@coh.org
Glaxo Smith Kline (GSK) Cancer - Lung Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Active, not recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) Recruiting
City of Hope
Elizabeth Budde, MD
626-218-2405
Kite Pharma Cancer - Lymphoma A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma Recruiting
City of Hope
Elizabeth Budde, MD, PhD
626-218-2405
ebudde@coh.org
City of Hope Cancer - Lymphoma Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) Recruiting
City of Hope
Cara Nolan
626-218-3241
canolan@coh.org
Juno Therapeutics Cancer - Lymphoma An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting
City of Hope
Alex Herrera, MD
626-218-2405
aherrera@coh.org
Kite Pharma Cancer - Lymphoma Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
City of Hope
Mihaela Cristea, MD
626-218-9200
mcristea@coh.org
Torque Therapeutics, Inc. Cancer - Lymphoma TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Lymphoma Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Lymphoma (HIV-Related) Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting
City of Hope
Leslie Popplewell, MD
626-218-2405
lpopplew@coh.org
Novartis Pharmaceuticals Cancer - Lymphona Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Adaptimmune Cancer - Myeloma NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
City of Hope
Myo Htut, MD
626-218-2405
mhtut@coh.org
Janssen Research & Development, LLC. Cancer - Myeloma A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) Recruiting
City of Hope
Myo Htut, MD
626-218-2405 ext 82405
mhtut@coh.org
Juno Therapeutics Cancer - Myeloma Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) Recruiting
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting

Pages

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News